Here Are My Top 4 Stocks to Buy in October

The article presents four stocks as potential Q4 opportunities, highlighting Viking Therapeutics’ VK2735 weight-loss drug, Alphabet’s Google Cloud growth of 82% year over year and SoFi’s 40% adjusted-revenue growth to $1.2 billion in Q2. SoFi raised full-year revenue guidance to $4.75 billion–$4.85 billion, while MercadoLibre reported nearly $10.2 billion in Q2 revenue, up 50% year over year. Analysts’ consensus 12-month price target for MercadoLibre is $2,295.31, 36% above its then-current price; these are the article’s bullish views, not reported market reactions.

Analysis

The opportunity set is not equally investable: GOOG and MELI have operating evidence to test over the next earnings cycle, SOFI has a credibility and composition problem, and VKTX remains clinical optionality. For GOOG, the second-order payoff is not simply AI monetization: winning cloud workloads can improve distribution for Gemini and enterprise tools, while search remains a funding source. But cloud growth alone does not establish durable share gains or attractive incremental margins; check cloud operating profit, backlog/conversion, and capex before paying for the thesis. Relative strength versus MSFT and AMZN is the cleaner expression than an unhedged AI narrative.

MELI's shipping spend is a customer-acquisition wager. It works only if higher engagement converts into repeat purchases, payments adoption, and better cohort economics; otherwise revenue growth can coexist with margin dilution. Brazil competition, FX, and credit quality are key 1–3 month checks, with network effects a 6–18 month thesis. SOFI's reported growth may not resolve questions about platform-client concentration, credit performance, or earnings quality; growth in members is not equivalent to durable profitable cross-selling. VKTX's monthly-maintenance proposition is early-stage and should not be capitalized as near-term revenue: trial data can create sharp upside, but failure or delay can reset probability-weighted value. Overall, the article's bullish framing understates execution and valuation risk; upcoming reports are catalysts, not proof. Verify the actual reporting calendar before positioning.

Key Decisions for Investors

• Prefer a measured long GOOG / short MSFT relative-value position into earnings rather than a broad AI trade. Add only if Google Cloud growth is accompanied by improving operating economics; trim or exit if growth decelerates materially or margins/capex worsen without evidence of monetization.
• Consider MELI on weakness or in staged entries, not as a price-target trade. The thesis is confirmed by sustained engagement translating into stronger repeat purchase/payment activity without continued deterioration in margins; reassess if Brazil shipping economics worsen, credit losses rise, or FX overwhelms operating progress.
• Keep SOFI at watchlist or small-risk sizing until the next report clarifies Galileo client replacement, technology-platform revenue trajectory, loan performance, and the composition of adjusted results. Falsifiers include renewed platform contraction or worsening credit metrics; headline member growth alone is insufficient.
• Treat VKTX as a catalyst-driven, limited-size biotech position only for investors able to absorb trial volatility. Do not assign meaningful value to monthly dosing before later-stage evidence; monitor trial design, efficacy, tolerability, and regulatory updates, with negative data or a material delay as exit triggers.